Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.62 |
| ▸ | IDO1 | P14902 | 3/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GALR3 | O60755 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDO2 | P48775 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FER | P16591 | 1/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16760895 | 1.00 | LRRK2 (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL1898719 | 1.00 | LRRK2 (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| Hydrochloric Acid SCHEMBL11498808 | 0.98 | LRRK2 (0.61) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL7051809 | 0.89 | MAOA (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL8874278 | 0.89 | MAOA (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL7051810 | 0.89 | MAOA (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL7050065 | 0.89 | MAOA (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL7050064 | 0.89 | MAOA (0.62) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL8874034 | 0.87 | MAOA (0.60) | LRRK2IDO1AGTR1KMT2AGALR3 | |
| SCHEMBL8874032 | 0.87 | MAOA (0.60) | LRRK2IDO1AGTR1KMT2AGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632948-B2 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2009-12-15 | — | — | US | claimed |
| EP-1707187-B1 | Reductive colorant for keratin fibres | WELLA AG (DE) | 2007-08-01 | — | — | EP | claimed |
| US-20060230548-A1 | Reductive colorant for keratin fibres | THE PROCTER & GAMBLE COMPANY | 2006-10-19 | — | — | US | claimed |
| WO-2006107595-A1 | REDUCTIVE COLORANT FOR KERATIN FIBRES | THE PROCTER & GAMBLE COMPANY (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1707187-A1 | Reductive colorant for keratin fibres | Wella Aktiengesellschaft (DE) | 2006-10-04 | — | — | EP | claimed |
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1532146-B1 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2006-03-01 | — | — | EP | claimed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| EP-1532146-A2 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| EP-0869958-B1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | claimed |
| WO-2004018466-A2 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-03-04 | — | — | WO | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | claimed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | claimed |
| US-5192792-A | Isatine derivatives, and their method of use | WARNER-LAMBERT COMPANY (US) | 1993-03-09 | — | — | US | claimed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | IDO2, IDO1, TPH2 | LRRK2 1926/4885IDO1 2/4885AGTR1 587/4885 |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | LRRK2 1548/4885IDO1 518/4885AGTR1 269/4885 |
| US-20060230548-A1 | Reductive colorant for keratin fibres | KRT18, COX6C, CYC1 | LRRK2 3974/4885IDO1 2185/4885AGTR1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.